| Bioactivity | Sodium Butyrate (Butanoic acid sodium salt) is a histone deacetylase (HDAC) inhibitor, with anti-tumor effects in several cancers. | ||||||||||||
| Invitro | Sodium Butyrate induces morphological changes, inhibits cell proliferation and impairs cell viability in NPC cells. Sodium Butyrate (1, 5, 10 mM) is cytotoxic to NPC cells, inducing a dose- and time-dependent decrease in cell viability, in both 5-8F and 6-10B cells. Sodium Butyrate induces nasopharyngeal carcinoma cell apoptosis by activating the mitochondrial apoptotic axis. Moreover, SOCE inhibition and disruption of the CRAC channel can attenuate the apoptosis induced by Sodium Butyrate[1]. Sodium butyrate significantly decreases cell viability, accompanied by reduced levels of p-mTOR and PCNA protein. Sodium butyrate, in a dose-dependent manner, induces cell cycle arrest in G0/G1 phase and reduces the numbers of cells in S phase. In addition, relative expression of p21, p27, and pro-apoptosis bak genes, and protein levels of p21Waf1/Cip1, p27Kip1, cyclinD3, CDK4, and Cleave-caspase3 are increased by higher concentrations of sodium butyrate (1, 5, 10 mM), and the levels of cyclinD1 and CDK6 are reduced by 5 and 10 mM butyrate[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Sodium butyrate 相关抗体: | ||||||||||||
| In Vivo | Sodium Butyrate (300 mg/kg, s.c.) administration immediately after HI provided almost complete neuroprotection in comparison with non-treated animals. Sodium butyrate administration results in an increased number of microglial cells to 150% of vehicle-treated animals in the ipsilateral side. Sodium butyrate promotes the polarization of microglia from M1- to M2-like phenotype after neonatal hypoxia-ischemia[2]. Sodium butyrate (300 mg/kg, s.c.) in combination with AK-7 (20 mg/kg, i.p.) significantly alleviates this reduction of the time spent exploring new objects, ameliorates the reduction of the number of Ki67-positive cells and DCX-immunoreactive neuroblasts in the dentate gyrus of the mice. In addition, sodium butyrate reverses SIRT2-related age phenotypes[4]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||
| CAS | 156-54-7 | ||||||||||||
| Formula | C4H7NaO2 | ||||||||||||
| Molar Mass | 110.09 | ||||||||||||
| Appearance | 固体 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Huang W, et al. Inhibition of store-operated Ca2+ entry counteracts the apoptosis of nasopharyngeal carcinoma cells induced by sodium butyrate. Oncol Lett. 2017 Feb;13(2):921-929 [2]. Wang P, et al. Sodium butyrate triggers a functional elongation of microglial process via Akt-small RhoGTPase activation and HDACs inhibition. Neurobiol Dis. 2017 Dec 14;111:12-25. [3]. Jaworska J, et al. The potential neuroprotective role of a histone deacetylase inhibitor, sodium butyrate, after neonatal hypoxia-ischemia. J Neuroinflammation. 2017 Feb 10;14(1):34 [4]. Qiu Y, et al. Effect of sodium butyrate on cell proliferation and cell cycle in porcine intestinal epithelial (IPEC-J2) cells. In Vitro Cell Dev Biol Anim. 2017 Jan 27 [5]. Jung HY, et al. Sirtuin-2 inhibition affects hippocampal functions and sodium butyrate ameliorates the reduction in novel object memory, cell proliferation, and neuroblast differentiation. Lab Anim Res. 2016 Dec;32(4):224-230 |
Sodium butyrate
CAS: 156-54-7 F: C4H7NaO2 W: 110.09
Sodium Butyrate (Butanoic acid sodium salt) is a histone deacetylase (HDAC) inhibitor, with anti-tumor effects in severa
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.